Canadian Approval for Xpert™ MRSA Test and GeneXpert® System
go back to news archives| Cepheid has announced that Health Canada has issued a medical device license for the Xpert™ MRSA test for the rapid detection of Methicillin Resistant Staphylococcus aureus (MRSA) on nasal swabs and the GeneXpert® System. The license enables access to the Canadian HAI Market; market expenditures for MRSA surveillance are expected to reach $80 million by 2012. Xpert MRSA test results are available in approximately 70 minutes thereby enabling rapid identification of carriers of the potential pathogen in less than two hours, from the acquisition of the patient sample to returning the result to the floor. The availability of the Xpert MRSA test and the GeneXpert System is expected to help enable Canadian healthcare organizations to implement more efficient infection control measures, leading to lower hospital acquired infection rates and improved patient care. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Cepheid View Company Information
Posted on February 1, 2008
advertisement
advertisement
advertisement
advertisement
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
Mycotoxin Detection and Analysis: Strategies to Support Your Testing Program
-
15th Conference of The World Mycotoxin Forum® – WMFmeetsSalzburg
-
ESCMID European Congress of Clinical Microbiology and Infectious Diseases
-
IBQC 2025
-
IFU Technical Workshop 2025
-
Validation of Water Systems for Microbial Control
-
USP Chapter <86> and the Move to Recombinant Methods
-
Free Expert Webinar: Advancing Drinking Water Microbiology Testing Compliance & Efficiency
-
British Society For Microbial Technology 40th Anniversary Microbiology Conference
-
Sampling and Microbial Testing of Water and Data Trending
